0.06
+3.70%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Prescient Therapeutics
Its shares trade on ASX under the ticker PTX.AX. It has been listed since 12 June 2013. In the fiscal year to 30 June 2025, it reported revenue of A$4.4m and a net loss of A$7.3m. At that date it held total assets of A$14.6m and shareholders' equity of A$11.4m.
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2013-06-12. The firm is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The firm is engaged in developing compounds to treat a range of solid and hematological cancers. The company is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Jun 2013
- Employees
- 3
- Website
- prescienttherapeutics.com ↗
Leadership
Pay as last reported
- Mr. Steven EngleNon-Executive Chairman of the BoardA$120,413
- Mr. James McdonnellChief Executive Officer
- Ms. Melanie LeydinChief Financial Officer, Company SecretaryA$158,400
- Dr. James CampbellNon-Executive DirectorA$72,102
- Dr. Allen EbensNon-Executive DirectorA$74,487
- Dr. Ellen FeigalNon-Executive Independent Director
- Dr. Gavin ShepherdNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Prescient Therapeutics Ltd has a robust research and development department, which enables them to develop innovative therapies and stay ahead of competitors in the market.
- The company has a diverse pipeline of product candidates targeting various diseases, providing them with multiple opportunities for revenue generation.
Weaknesses
- Prescient Therapeutics Ltd may face challenges due to limited financial resources, which could impact their ability to conduct extensive clinical trials or expand their operations.
- The company relies on collaborations and partnerships for research, development, and commercialization activities. This dependence may limit their control over decision-making processes and profits.
Opportunities
- The pharmaceutical industry is witnessing an increasing demand for novel and effective treatment options. Prescient Therapeutics Ltd can capitalize on this opportunity by leveraging their strong research capabilities and introducing groundbreaking therapies.
- The company can consider expanding into emerging markets, where there is a rising need for advanced healthcare solutions. This expansion can provide them with a new customer base and revenue streams.
Threats
- Prescient Therapeutics Ltd faces intense competition from established pharmaceutical companies and emerging biotech firms. This competitive landscape can pose challenges in terms of market share acquisition and pricing pressures.
- The company operates in a highly regulated industry. Compliance with rigorous regulatory requirements and lengthy approval processes can significantly delay the development and commercialization of their product candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.